Evidence map›Paper›PMID 37615014›Full record

ArticleBeilstein journal of nanotechnology2023

Industrial perspectives for personalized microneedles.

Remmi Danae Baker-Sediako, Benjamin Richter, Matthias Blaicher, Michael Thiel, Martin Hermatschweiler

Abstract read
In one paragraph

Article in Beilstein journal of nanotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Remmi Danae Baker-SediakoNanoscribe Gmbh & Co, Hermann-von-Helmholtz-Platz 6, 76344 Eggenstein-Leopoldshafen, Germany.ORCID https://orcid.org/0000-0002-8901-4489
Benjamin RichterNanoscribe Gmbh & Co, Hermann-von-Helmholtz-Platz 6, 76344 Eggenstein-Leopoldshafen, Germany.
Matthias BlaicherNanoscribe Gmbh & Co, Hermann-von-Helmholtz-Platz 6, 76344 Eggenstein-Leopoldshafen, Germany.
Michael ThielNanoscribe Gmbh & Co, Hermann-von-Helmholtz-Platz 6, 76344 Eggenstein-Leopoldshafen, Germany.
Martin HermatschweilerNanoscribe Gmbh & Co, Hermann-von-Helmholtz-Platz 6, 76344 Eggenstein-Leopoldshafen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microneedles and, subsequently, microneedle arrays are emerging miniaturized medical devices for painless transdermal drug delivery. New and improved additive manufacturing methods enable novel microneedle designs to be realized for preclinical and clinical trial assessments. However, current literature reviews suggest that industrial manufacturers and researchers have focused their efforts on one-size-fits-all designs for transdermal drug delivery, regardless of patient demographic and injection site. In this perspective article, we briefly review current microneedle designs, microfabrication methods, and industrialization strategies. We also provide an outlook where microneedles may become personalized according to a patient's demographic in order to increase drug delivery efficiency and reduce healing times for patient-centric care.

Indexed as

3D printingmicrofabricationmicroneedlespersonalized medicinetransdermal drug deliverytwo-photon polymerization

Identifiers

PMID37615014
PMCPMC10442529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.